Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Descending) Package Effective Date Package Discontinuation Date Status
82868-0026-30 82868-0026 Estradiol Estradiol 2.0 mg/1 Hormonal Therapy Estrogen Oral Nov. 9, 2023 In Use
82868-0038-30 82868-0038 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Feb. 5, 2024 In Use
82868-0038-90 82868-0038 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Jan. 18, 2024 In Use
83774-0100-60 83774-0100 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 27, 2024 In Use
83774-0101-12 83774-0101 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 27, 2024 In Use
00003-4040-12 00003-4040 Repotrectinib Augtyro 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Dec. 5, 2023 In Use
00003-4040-60 00003-4040 Repotrectinib Augtyro 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Dec. 5, 2023 In Use
00310-9500-01 00310-9500 Capivasertib TRUQAP 160.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov. 16, 2023 In Use
63020-0210-21 63020-0210 Fruquintinib Fruzaqla 1.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 8, 2023 In Use
63020-0225-21 63020-0225 Fruquintinib Fruzaqla 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 8, 2023 In Use
82448-0050-18 82448-0050 Nirogacestat OGSIVEO 50.0 mg/1 Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Oral Nov. 27, 2023 In Use
63187-0256-20 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 1, 2017 In Use
63187-0256-30 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 1, 2017 In Use
63187-0256-05 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 28, 2022 In Use
63187-0256-10 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 28, 2022 In Use
63187-0256-15 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 28, 2022 In Use
63187-0256-06 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 24, 2024 In Use
63187-0256-12 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 26, 2024 In Use
00078-0649-30 00078-0649 Imatinib Mesylate Gleevec 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 23, 2014 In Use
00078-0649-13 00078-0649 Imatinib Mesylate Gleevec 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 1, 2024 In Use
60687-0375-01 60687-0375 DRONABINOL DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic Cannabinoid Oral July 16, 2018 Sept. 30, 2025 In Use
60687-0375-21 60687-0375 DRONABINOL DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic Cannabinoid Oral March 31, 2024 In Use
43826-0066-04 43826-0066 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral Dec. 1, 2022 In Use
72162-2149-00 72162-2149 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 7, 2019 In Use
00002-5340-60 00002-5340 Selpercatinib RETEVMO 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use

Found 10,000 results in 10 milliseconds — Export these results